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Summary
 
The induction of optimal systemic antitumor immunity involves the priming of both CD4
 
1
 
and CD8
 
1
 
 T cells specific for tumor-associated antigens. The role of CD4
 
1
 
 T helper cells (Th)
in this response has been largely attributed to providing regulatory signals required for the
priming of major histocompatibility complex class I restricted CD8
 
1
 
 cytolytic T lymphocytes,
which are thought to serve as the dominant effector cell mediating tumor killing. However,
analysis of the effector phase of tumor rejection induced by vaccination with irradiated tumor
cells transduced to secrete granulocyte/macrophage colony-stimulating factor indicates a far
broader role for CD4
 
1
 
 T cells in orchestrating the host response to tumor. This form of immu-
nization leads to the simultaneous induction of Th1 and Th2 responses, both of which are re-
quired for maximal systemic antitumor immunity. Cytokines produced by these CD4
 
1
 
 T cells
activate eosinophils as well as macrophages that produce both superoxide and nitric oxide.
Both of these cell types then collaborate within the site of tumor challenge to cause its destruc-
tion.
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T
 
he exquisite specificity of antigen recognition by the T
cell arm of the immune response provides an important
basis for cancer immunotherapy. The ability to discriminate
tumor cells from normal tissues is critical for enabling effec-
tive tumor destruction while minimizing toxicity. Indeed,
the isolation of tumor-specific T cells from cancer patients
has fueled the search for tumor-associated antigens. The
molecular identification of several such antigens, particularly
in human melanoma, has enabled the pursuit of vaccine strat-
egies that specifically target defined tumor antigens (1–3).
In the setting where relevant tumor rejection antigens
have yet to be defined, vaccination with modified whole
tumor cells as the antigen source has been explored as a
means to prime systemic antitumor immunity. The host re-
sponse to this form of vaccination has been shown to be
significantly enhanced when the immunizing tumor cells
are transduced with genes encoding cytokines or other
molecules involved in the regulation of immune responses
(4). For both tumor cell–based and defined antigen vaccine
strategies, T cell subset depletion studies have usually dem-
onstrated the requirement for both CD4
 
1
 
 and CD8
 
1
 
 T
cells for systemic tumor rejection to occur.
Given that most nonhematopoietic tumors express MHC
class I molecules, which serve as the restricting element for
CD8
 
1
 
 T cell recognition, but do not express MHC class II
molecules, which are required for CD4
 
1
 
 T cell recogni-
tion, it has been assumed that the predominant tumoricidal
effector mechanism is killing by CD8
 
1
 
 CTL. The require-
ment for CD4
 
1
 
 T cells in these responses has been attrib-
uted to providing help during priming to achieve full acti-
vation and effector function of tumor-specific CTL.
Indeed, MHC class I restricted CD8
 
1
 
 T cells that specifi-
cally lyse tumor cells in vitro are frequently measured to
document vaccine efficacy and to serve as a surrogate end
point in clinical tumor vaccine trials.
However, several lines of evidence suggest a broader role
for CD4
 
1
 
 T cells in mediating other significant antitumor
effector functions. First, studies in which mice were vacci-
nated several weeks before a live tumor challenge demon-
strated that although immunologically intact mice were
able to reject tumor, the depletion of CD4
 
1
 
 T cells with a
mAb just before the tumor challenge resulted in the com-
plete loss of tumor rejection (5). In these experiments, T
cell help for CTL priming was fully available at the time of
vaccination. This outcome suggests that CD4
 
1
 
 T cells play
a more direct role in the effector phase of tumor rejection.
Second, we have demonstrated previously that vaccination
against tumor cells completely lacking MHC class I expres-
sion resulted in tumor rejection that was comparable to that
seen against a challenge with an MHC class I positive vari-
  
2358
 
The Role of CD4
 
+
 
 T Cells in Antitumor Immunity
 
ant of the same tumor (6). Depletion of either CD4
 
1
 
 T
cells or NK cells, but not CD8
 
1
 
 T cells, resulted in the in-
ability to reject the MHC class I negative variant, suggest-
ing that CD4
 
1
 
 T cells may provide help as well as a mea-
sure of antigen specificity to effector cells of the immune
response that do not themselves have the capacity for anti-
gen-specific recognition.
To dissect the mechanism of CD4
 
1
 
 T cell effector func-
tion during tumor rejection, we studied immune responses
induced by a genetically modified whole cell vaccine. A
comparison of genetically modified whole cell vaccines, us-
ing the B16 melanoma (7) transduced with a large set of
individual cytokine genes, demonstrated that GM-CSF–
transduced vaccines generated potent and long-lasting sys-
temic antitumor immunity that was dependent on both
CD4
 
1
 
 and CD8
 
1
 
 T cells (5). Induction of immunity
against the poorly immunogenic B16 tumor appears to be
due to the ability of the locally produced GM-CSF to acti-
vate bone marrow–derived APCs during the priming phase
to process and present tumor antigens to both CD4
 
1
 
 and
CD8
 
1
 
 T cells (8–10). In the following studies, we were
able to demonstrate that rather than simply providing help
for CD8
 
1
 
 T cells, CD4
 
1
 
 T cells express both Th1 and Th2
cytokines and recruit other antitumor effector cells in addi-
tion to CD8
 
1
 
 T cells.
 
Materials and Methods
 
In Vivo Vaccination: Tumor Challenge Experiments.
 
6–8-wk-old
female C57BL/6 mice were obtained from the National Cancer
Institute (Bethesda, MD) and housed in the Johns Hopkins On-
cology Center Animal Facility. In the same facility, CD4
 
2
 
/
 
2
 
,
CD8
 
2
 
/
 
2
 
, 
 
g
 
-IFN
 
2
 
/
 
2
 
, IL-4
 
2
 
/
 
2
 
, IL-5
 
2
 
/
 
2
 
, X-CGD, and inducible
nitric oxide synthase (iNOS
 
2
 
/
 
2
 
)
 
1
 
 mice that had been backcrossed
to the C57BL/6 background for greater than seven generations were
bred, and female offspring were used for experiments starting at 6–8
wk of age. CD4
 
2
 
/
 
2
 
 and CD8
 
2
 
/
 
2
 
 mice were gifts from Dr. Tak Mak
(Ontario Cancer Institute, University of Toronto, Toronto, Can-
ada). IL-4
 
2
 
/
 
2
 
, 
 
g
 
-IFN
 
2
 
/
 
2
 
, and iNOS
 
2
 
/
 
2
 
 mice were obtained from
The Jackson Laboratories (Bar Harbor, ME). IL-5
 
2
 
/
 
2
 
 and X-CGD
mice were gifts of Dr. Eric Pearlman (Case Western Reserve, Cleve-
land, OH) and Dr. Mary Dinauer (Indiana University School of
Medicine, Indianapolis, IN), respectively. In brief, mice were in-
jected subcutaneously in the left flank with 10
 
6
 
 irradiated (50 Gy)
B16 tumor cells transduced with the GM-CSF gene (B16-GM-
CSF), resulting in the production of 420 ng GM-CSF/10
 
6
 
 cells/24 h
(5). 2 wk later, mice were challenged in the right flank with 10
 
5
 
 live
nontransduced B16 cells (B16-WT). B16-GM-CSF and B16 wild-
type cells were provided by Dr. Glenn Dranoff (Dana Farber Cancer
Institute, Boston, MA). Before injection, cells were harvested while
in log phase growth from in vitro cell culture by trypsinization and
were washed three times in serum-free 1
 
3
 
 HBSS. All injections
were in 0.1-ml vol. All experimental groups were matched for both
age and sex. Data from the immunization challenge experiments are
presented as Kaplan-Meier plots, representing the percentage of ani-
mals without detectable tumor. Mice were monitored twice weekly
for tumor growth. All individual experiments included a minimum
of 10 mice/group, and data from at least two repeat experiments are
pooled in the Kaplan-Meier analyses.
 
Quantitative RT-PCR.
 
TRIZOL (GIBCO BRL, Gaithers-
burg, MD) was used to extract total RNA from lymphocytes
draining the site of s.c. vaccination with irradiated B16-GM-CSF
and from the site of s.c. challenge with live B16-WT cells. The
SUPERSCRIPT Preamplification System (GIBCO BRL) was used
to reverse transcribe total RNA to cDNA. The cDNA and cytokine
competitor (a gift from Dr. Richard Locksley, University of Califor-
nia San Francisco, San Francisco, CA) were then PCR amplified for
 
g
 
-IFN (forward: 5
 
9
 
-CATTGAAAGCCTAGAAAGTCTG-3
 
9
 
; re-
verse: 5
 
9
 
-CTCATGAATGCATCCTTTTTCG-3
 
9
 
), yielding 267-
and 320-bp fragments, respectively. The cDNA and cytokine
competitor were also PCR-amplified for IL-4 (forward: 5
 
9
 
-CATCG-
GCATTTTGAACGAGGTCA-3
 
9
 
; reverse: 5
 
9
 
-CTTATCGAT-
GAATCCAGGCATCG-3
 
9
 
), yielding 240- and 360-bp fragments,
respectively. The following cycling conditions were used: 94
 
8
 
C
for 3 min, then 35 cycles at 94
 
8
 
C for 40 sec, 60
 
8
 
C for 20 sec, and
72
 
8
 
C for 40 sec, followed by a final extension at 72
 
8
 
C for 10 min.
All reactions used PCR Gem 100 (Perkin-Elmer Corp., Nor-
walk, CT) for hot start and 
 
32
 
P-labeled primers for later determi-
nation of final product yield. The products were then resolved on
a 6% polyacrylamide gel, dried on a Bio-Rad gel dryer (Bio-Rad
Lab., Hercules, CA), and the final product yields were quantified
on a PhosphorImager scanner (Molecular Dynamics, Sunnyvale,
CA). The cytokine cDNA was held constant and the competitor
concentration was varied until the yield of the two products were
at least within threefold of each other. The initial concentration of
the cytokine in the PCR reaction was then calculated by the fol-
lowing formula: 
 
initial cytokine level
 
 
 
5
 
 (
 
cytokine product signal
 
/
 
com-
petitor product signal
 
) 
 
3
 
 (
 
starting concentration of competitor
 
). The num-
ber of copies per microgram of total RNA was then calculated.
 
Immunohistochemistry for iNOS.
 
The biopsy of the tumor
challenge site was removed and flash frozen in O.C.T. compound
(Sakura Finetek USA, Inc., Torrance, CA) and dry-ice cooled
isopentane. 5-
 
m
 
m tissue sections were fixed for 10 min in acetone
and washed with TBS. Sections were quenched with a solution
of 0.05% H
 
2
 
O
 
2
 
, 1% normal goat serum, and 0.5% milk for 30
min and then blocked with TBS/milk/1% normal goat serum for
10 min. The sections were then incubated with either 
 
a
 
-iNOS
antibody (11) or Mac-3 antibody (American Type Culture Col-
lection, Rockville, MD) for 60 min. After washing, sections were
incubated with biotinylated secondary antibody, goat 
 
a
 
-rabbit
IgG Fc for the 
 
a
 
-iNOS antibody (Jackson ImmunoResearch
Labs, Inc., West Grove, PA) and rabbit 
 
a
 
-rat IgG (Vector Labs,
Inc., Burlingame, CA) for the Mac-3 antibody, for 30 min. After
washing, sections were incubated with ExtAvidin alkaline phos-
phatase (Sigma Chemical Co., St. Louis, MO) for 60 min. Slides
were washed, and then a Fast Red substrate was used for detection.
 
Results
 
Antitumor Immunity Requires CD4
 
1
 
-dependent Effector Cells
in Addition to CD8
 
1
 
 T Cells.
 
Wild-type, CD4 knockout
(CD4
 
2
 
/
 
2
 
) (12) and CD8 knockout (CD8
 
2
 
/
 
2
 
) mice (13) were
vaccinated subcutaneously in the left flank with 10
 
6
 
 irradiated
B16-GM-CSF (B16 cells transduced with GM-CSF) and
challenged 2 wk later in the right flank with 10
 
5
 
 wild-type
(nontransduced) B16 melanoma cells. This dose of wild-type
B16 cells is roughly 100-fold greater than the minimum dose
that forms tumors in nonvaccinated C57BL/6 wild-type
mice, but is rejected in the majority of animals previously
 
1
 
Abbreviations used in this paper:
 
 iNOS, inducible nitric oxide synthase;
NO, nitric oxide. 
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vaccinated with B16-GM-CSF. In contrast to vaccinated
wild-type mice, immunization of CD4
 
2
 
/
 
2
 
 mice failed to
prime a systemic immune response capable of rejecting
this tumor challenge (Fig. 1). Interestingly, although simi-
larly immunized CD8
 
2
 
/
 
2
 
 mice (13) are impaired in their
ability to reject this tumor challenge, a significant fraction
of CD8
 
2
 
/
 
2
 
 mice mounted a successful tumor rejection. In
several experiments over a range of tumor challenge doses,
the fraction of immunized CD8
 
2
 
/
 
2
 
 mice that rejected a tu-
mor challenge was roughly half of that observed in immu-
nized wild-type mice (data not shown). In contrast, no
measurable antitumor responses were ever demonstrated in
CD4
 
2
 
/2 mice. These observations directly demonstrate the
existence of other CD41 T cell–dependent effector mecha-
nisms besides MHC class I restricted CD81 CTL.
Vaccination with B16-GM-CSF Induces the Expression of
Both Th1 and Th2 Cytokines. The best characterized func-
tion of CD41 T cells is the elaboration of cytokines that
regulate downstream effector function of both cellular and
humoral immunity. The division of CD41 T cell or Th
function into Th1 and Th2 phenotypes originally was
based on the observation that murine T helper clones pro-
duced certain cytokines in a mutually exclusive fashion
(14–16). Subsequent studies indicated that Th1 cytokines,
such as g-IFN, as well as cytokines that promote Th1 dif-
ferentiation, such as IL-12, inhibit Th2 development (17–
19), whereas Th2 cytokines, such as IL-4 and IL-10, inhibit
Th1 development (20–22). Taken together, these findings
suggested that productive in vivo Th responses would de-
velop uniquely along either a Th1 or a Th2 pathway and
that the ensuing immunologic effector mechanisms would
reflect the distinct pattern of cytokine production associ-
ated with the particular pathway of Th differentiation.
We used the B16 vaccination-challenge system to evalu-
ate the expression of g-IFN, the prototypical Th1 cyto-
kine, and IL-4, the prototypical Th2 cytokine at the site of
tumor challenge. Competitive quantitative PCR analysis of
g-IFN and IL-4 mRNA at the site of tumor challenge
demonstrated that both of these messages were significantly
increased, relative to naive mice (Fig. 2 A). The increase in
g-IFN and IL-4 mRNA was similar in vaccinated CD82/2
mice to that observed in wild-type mice. In contrast,
g-IFN and IL-4 mRNA were not increased at the tumor
challenge site in vaccinated CD42/2 mice, indicating that
both g-IFN and IL-4 production are dependent upon acti-
vated CD41 T cells. These results contrast with the find-
ings in other studies on immune responses to parasites and
intracellular bacteria that demonstrated that the production
of one or the other cytokine ultimately dominates the ef-
fector phase of the response, leading to a polarized pattern
of Th cytokine secretion that is associated with the ability
to clear the infection (23–29).
Vaccination with B16-GM-CSF Requires Both Th1 and
Th2 Cytokines for Maximal Systemic Tumor Immunity. To
determine whether the Th1 cytokine, g-IFN, or the Th2
cytokine, IL-4, was required for the induction of systemic
antitumor immunity by B16-GM-CSF, vaccination-chal-
lenge experiments were performed in g-IFN2/2 and
IL-42/2 mice (30, 31). As demonstrated in Fig. 2 B, protec-
tive immunity against B16 melanoma challenge was signifi-
cantly decreased in both sets of cytokine gene knockout
mice. In the case of g-IFN2/2 mice, protection against
tumor challenge was completely eliminated, whereas in
IL-42/2 mice, protection was reduced by z50% relative to
vaccinated wild-type mice. Thus, in accordance with the
PCR results in Fig. 2 A, and in contrast to the immune re-
sponse in previous infectious models, induction of maximal
systemic antitumor immunity was dependent on both the
Th1 and the Th2 components of the immune response.
Eosinophils Are a Th2 Effector Cell. To further define
potential downstream effector mechanisms mediating tu-
mor rejection, tissue from the tumor challenge site was ex-
amined. As seen in Fig. 3, eosinophils are one of the most
prominent infiltrating cell types at the site of tumor chal-
lenge in vaccinated mice (in addition to macrophages and
lymphocytes). Eosinophils represent a candidate Th2-depen-
dent antitumor effector cell. Their differentiation from my-
eloid progenitors requires the Th2 cytokine IL-5 (32), and
their recruitment from the blood into tissues is partially de-
pendent on IL-4 (33). Indeed, the dense eosinophil infil-
trate at the tumor challenge site is reminiscent of that seen
in IL-4 transduced tumor cells after in vivo injection (34,
35). Eosinophils are completely absent from the tumor
challenge site in vaccinated CD42/2 mice and are z80%
reduced in vaccinated IL-42/2 mice, indicating that CD41
T cell–derived IL-4 is critical for their recruitment. In con-
trast, the challenge site of vaccinated CD82/2 and g-IFN2/2
mice demonstrated an eosinophil infiltrate similar to that of
wild-type mice.
Several lines of evidence support the notion that the in-
filtrating eosinophils are important Th2 dependent antitu-
mor effectors, rather than simply inactive bystanders. First,
protection against tumor challenge was significantly dimin-
Figure 1. The contribution of CD41 and CD81 T cell subsets to the
systemic response to B16-GM-CSF vaccination. Wild-type, CD42/2,
and CD82/2 mice were injected subcutaneously in the left flank with 106
irradiated (50 Gy) B16-GM-CSF cells. Mice were challenged 2 wk later
in the right flank with 105 live B16-WT cells, and examined twice
weekly for the development of tumor. These data represent the results of
three different experiments in which each experimental group consisted
of 10 mice.2360 The Role of CD4+ T Cells in Antitumor Immunity
ished in vaccinated IL-52/2 mice (Fig. 2 B) (36). Because
IL-5 is critical for differentiation of bone marrow progeni-
tors into eosinophils, mature eosinophils fail to develop in
IL-52/2 mice. Second and most importantly, the loss of
systemic antitumor immunity was associated with the ab-
sence of eosinophils at the tumor challenge sites in IL-52/2
mice (Fig. 3). Third, earlier studies of both mouse and hu-
man tissues revealed eosinophil degranulation at the tumor
site, as demonstrated by the presence of eosinophil granule
specific major basic protein in the interstitial space (37).
This degranulation is a characteristic feature of activated
eosinophils (38).
Tumor-specific CD81 T Cells Are Not Sufficient for Maximal
Tumor Immunity. A number of potential antitumor effec-
tor mechanisms could depend on the Th1 component. The
majority of studies on antitumor immunity have focused on
CTL generation as the critical Th1-dependent effector
mechanism. We wished to examine whether the priming
of tumor-specific CTL was impaired in g-IFN knockout
mice, which might account for the marked dependence of
successful tumor rejection on the ability to produce this cy-
tokine. Interestingly, induction of CTL specific for an im-
munodominant MHC class I restricted B16 antigen derived
from the tyrosinase related protein-2 protein (39) was iden-
tical in wild-type, IL-42/2, and g-IFN2/2 mice (Fig. 4).
Although CTL induction was normal in the cytokine gene
knockout mice, tyrosinase related protein-2–specific CTL
could not be detected in B16-GM-CSF vaccinated CD42/2
mice. This finding is consistent with recent reports that
have identified CD154/CD40 interactions between CD41
T cells and APCs as mediators of T cell help for CTL prim-
ing via the cross-priming pathway (40–42). The fact that
there was not a loss of antitumor CTL activity associated
with the corresponding loss of in vivo tumor protection in
the cytokine gene knockout mice does not mean that CTL
are unimportant as antitumor effectors, but it does indicate
that CTL alone are insufficient to eliminate tumor chal-
lenges.
Antitumor Immunity Requires Production of Nitric Oxide
(NO) and Superoxide From Tumoricidal Macrophages. An-
other potential Th1 effector mechanism is NO production
by iNOS in activated macrophages. NO production by
macrophages has been demonstrated to have tumoricidal
activity both in vitro and in vivo (43–54). Indeed, immu-
nohistochemical staining at the challenge site of B16-GM-
CSF vaccinated wild-type mice showed an abundant infil-
tration of macrophages (Fig. 5 B). This infiltrate was still
evident in the cytokine gene knockout mice, but was ab-
sent in CD42/2 mice (Fig. 5 C). Infiltrating macrophages
stained strongly positive for iNOS in vaccinated wild-type
mice (Fig. 5 H). In contrast, despite the presence of large
numbers of macrophages in B16-GM-CSF vaccinated
g-IFN2/2 mice (Fig. 5 E), iNOS was virtually absent at the
challenge site in g-IFN2/2 mice (Fig. 5 K). iNOS expres-
Figure 2. The role of cytokines in the systemic immune response to vaccination
with B16-GM-CSF. (A) Mice were vaccinated with 106 irradiated (50 Gy) B16-
GM-CSF tumor cells and challenged 2 wk later in the opposite flank with 105
live B16-WT tumor cells. 4 d after live tumor challenge, mice were killed and
total RNA was extracted from a biopsy of the tumor challenge site. At least four
mice were used for each group. g-IFN and IL-4 mRNA levels were then deter-
mined by a competitive quantitative RT-PCR assay (14). Results are shown as
number of copies of g-IFN or IL-4 message per microgram of total RNA. (B)
Wild-type, g-IFN2/2, IL-42/2, and IL-52/2 mice were vaccinated with irradi-
ated B16-GM-CSF cells and challenged with B16-WT cells 2 wk later in the op-
posite flank, as in Fig. 1. These data represent the results of three different exper-
iments in which each experimental group consisted of 10 mice.2361 Hung et al.
sion was present at the challenge site of IL-42/2 mice (Fig.
5 L), although levels were reduced relative to wild-type
mice. The reduction in iNOS levels in IL-42/2 mice was
somewhat unexpected, given that IL-4 inhibits iNOS ex-
pression in macrophages (55–57). One possible explanation
for this reduction in IL-42/2 mice could be the compensa-
tory hyperexpression of other cytokines, such as IL-10, that
indirectly inhibit iNOS expression through the inhibition
of TNF-a expression, a costimulator for iNOS induction
(21, 22, 58–60). It is also possible that the decreased iNOS
expression is secondary to the decreased tissue eosinophilia,
as eosinophils themselves are known to express TNF-a
(61, 62). Furthermore, eosinophils also express eosinophil
peroxidase and macrophage inflammatory protein-1, both
of which induce TNF-a release from macrophages (63,
64). Therefore, it is possible that eosinophils function as a
positive modulator for iNOS release by macrophages. Fur-
thermore, the dramatic absence of iNOS expression in
g-IFN2/2 mice, which fail to reject tumor in response to
vaccination, suggests that NO production by tumor infil-
trating macrophages may represent an important in vivo
antitumor effector mechanism.
Direct functional evidence for the role of iNOS in tu-
mor rejection was sought in vaccination-challenge experi-
ments in iNOS2/2 mice. In accordance with the previous
immunohistochemical staining, vaccinated iNOS2/2 mice
show a substantial decrease in protection against challenge
with tumor (Table 1), thereby demonstrating the critical
role for NO in antitumor killing.
Activated phagocytes can also mediate killing through
the production of superoxide, which is produced by the
NADPH oxidase–enzyme complex. Mutations in the CYBB
gene which encodes the 91-kD glycoprotein component of
the oxidase (gp91phox) account for the X-linked form of
Figure 3. The dependence of eosinophil recruitment to the tumor challenge site on CD41 T cells and cytokines. Mice were vaccinated with 106
irradiated (50 Gy) B16-GM-CSF cells and challenged 2 wk later on the opposite flank with 105 live B16-WT cells. After 4 d, the site of live wild-type
tumor challenge was removed and sections were stained with hematoxylin and eosin. (A) Wild-type, (B) CD42/2, (C) CD82/2, (D) IL-42/2, (E) g-IFN2/2,
and (F) IL-52/2 C57BL/6 mice.
Figure 4. The role of CD41 T cells and cytokines in priming tumor-specific
CTL. Wild-type, CD42/2, g-IFN2/2, and IL-42/2 mice were vaccinated
with 106 irradiated (50 Gy) B16-GM-CSF tumor cells. After 2 wk, spleno-
cytes were isolated and cultured for 7 d with 5 mg/ml TRP-2 peptide and
10 U/ml IL-2. On day 7, live T cells were incubated with 51Cr-labeled
MC57G targets at the indicated effector to target ratios in the presence of
1 mg/ml TRP-2 peptide or irrelevant peptide. The percent peptide-specific
lysis is calculated as the difference between the percent specific lysis due to the
TRP-2 peptide and the percent specific lysis due to the irrelevant peptide.2362 The Role of CD4+ T Cells in Antitumor Immunity
chronic granulomatous disease, an immunodeficiency syn-
drome characterized by recurrent infections with catalase-
positive microorganisms. Phagocytes from chronic granu-
lomatous disease patients or genetic knockout mice of
gp91phox (X-CGD mice) (65) mount a severely defective
respiratory burst with little or no generation of superoxide
or hydrogen peroxide. X-CGD mice immunized with
B16-GM-CSF showed a substantial decrease in protection
against challenge with B16 tumor (Table 1), thereby impli-
cating superoxide in the antitumor response. The loss of
tumor protection in both the iNOS2/2 and X-CGD mice
indicates that both NO and superoxide involved in phago-
cytic killing play a major role in the antitumor effect in-
duced by B16-GM-CSF.
Discussion
Taken together, the experiments presented here demon-
strate that effective antitumor immunity is critically depen-
dent upon the CD41 T cell, which is responsible for or-
chestrating multiple immunologic effector arms, dependent
on both Th1 and Th2 cytokines. We have demonstrated
Figure 5. Macrophages and iNOS expression at the site of wild-type tumor challenge. Mice were vaccinated with 106 irradiated (50 Gy) B16-GM-CSF
tumor and challenged 2 wk later with 105 live B16-WT tumor. After 4 d, mice were killed and the live wild-type tumor challenge site was sectioned and
stained for macrophages (A–F) and iNOS (G–L) (24). (A) Control for macrophage staining: no primary antibody; (B) macrophages at site of tumor chal-
lenge in wild-type mice; (C) CD42/2 mice; (D) CD82/2 mice; (E) g-IFN2/2 mice; and (F) IL-42/2 mice; (G) control for iNOS staining: no primary an-
tibody; (H) iNOS at site of tumor challenge in wild-type mice; (I) CD42/2 mice; (J) CD82/2 mice; (K) g-IFN2/2 mice; and (L) IL-42/2 mice.2363 Hung et al.
previously that the priming phase of the immune response
to GM-CSF–secreting tumor cells involves the recruitment
of bone marrow–derived APCs which process and present
tumor antigens to both CD41 and CD81 T cells (10). In
this study, we have examined the effector mechanisms re-
quired for the successful rejection of tumor found at distant
sites. As the challenge tumor used in these studies is MHC
class II negative, the effector phase of the response also re-
quires processing of tumor antigens by infiltrating APCs for
presentation to CD41 T cells. These observations under-
score the critical role of bone marrow–derived APCs in
two phases of the antitumor immune response—priming of
de novo T cell responses (thought to be mediated largely
by activated dendritic cells) and amplification of the effec-
tor phase through the processing and presentation of tumor
antigen to memory CD41 T cells. Through the local re-
lease of cytokines, these cells direct the effector response,
recruiting and activating tumoricidal macrophages, eosino-
phils, and the other populations seen histologically. This
cooperative interaction between APC and memory CD41
T cell is the hallmark of a classic delayed type hypersensi-
tivity response.
The requirement for CD41 T cells in the effector phase
of an immune response to tumors that do not themselves
express MHC class II is consistent with earlier results in
adoptive transfer systems. Infusion of tumor-specific CD41
T cells was shown to be capable of eradicating the MHC
class II negative FBL-3 murine leukemia line (66). Class II
positive macrophages were found to be required to present
processed tumor antigens to CD41 T cells (67). Further-
more, several vaccine strategies that directly enhance the
priming of tumor-specific CD41 T cells have been shown
to augment the systemic rejection of MHC class II negative
tumors (68–71).
Previous studies in cancer immunology have focused
largely on Th1 effector mechanisms, and particularly on
CTL generation. Interestingly, CTL may play a smaller
role in eradication of the B16 challenge tumor than in
other cancer vaccine systems because of the expression of
Fas ligand by B16 (as well as by many human melanomas),
which may protect the tumor from direct CTL-mediated
killing (72). Instead, it appears that both macrophages and
eosinophils play a major role in the immune response
against B16 and probably act together to achieve more effi-
cient tumor killing. This is supported by previous studies
showing that (a) eosinophil peroxidase can synergize with
macrophage reactive oxygen intermediates to kill tumor
cells (73) and (b) peroxidases can catalyze the oxidation of
nitrite to generate further cytotoxic radicals (74). However,
neither macrophages nor eosinophils have an intrinsic ca-
pacity for tumor specificity. Instead, the tumor specificity
of these effectors is based on their activation by neighbor-
ing tumor-specific Th cells.
To date, the major effort in tumor antigen identification
has focused almost exclusively on antigens recognized by
tumor-specific, MHC class I restricted CTL. Several anti-
gen-specific vaccine strategies incorporating class I re-
stricted tumor antigens identified through these efforts are
being explored currently in animal models and early phase
clinical trials. In the absence of known MHC class II re-
stricted tumor antigens, such strategies rely on the effects of
adjuvants or incorporate surrogate class II antigens from in-
fectious pathogens to provide help for CTL induction. The
studies presented here suggest that although Th responses
generated by this type of vaccination may enhance CTL
induction during priming, they are unlikely to participate
in the effector phase that requires tumor-specific CD41 T
cell help. Ultimately, the optimal tumor antigen–specific
vaccine will ideally incorporate a panel of dominant tumor
antigens recognized by both CD41 and CD81 T cells.
The finding that GM-CSF transduced whole cell vac-
cines simultaneously induce Th1 and Th2 differentiation
contrasts with previous findings of in vivo immune re-
sponses to both intracellular bacteria and parasites. In resis-
tant mouse strains, such as C3H or C57BL/6, infection
with the intracellular parasite Leishmania major exclusively
induces a Th1 response, characterized by high g-IFN and
low IL-4 production (23–25). Furthermore, eradication of
L. major has been shown to be dependent upon g-IFN–
dependent stimulation of iNOS in macrophages (75–84).
Conversely, in susceptible mouse strains, such as BALB/c,
infection with L. major induces exclusively a Th2 immune
response, characterized by high IL-4 and low g-IFN pro-
duction (23–25, 28, 85). Based upon this altered pattern of
Table 1. The Role of iNOS and NADPH Oxidase in Mediating 
Tumor Rejection in Response to B16-GM-CSF Vaccination
WT
no vaccine
NOS2/2
no vaccine
WT
B16-GM-CSF
NOS2/2
B16-GM-CSF
Exp. 1 0/5 (0%) 0/5 (0%) 10/10 (100%) 6/10 (60%)
Exp. 2 0/5 (0%) 0/5 (0%) 9/10 (90%) 5/10 (50%)
WT
no vaccine
X-CGD
no vaccine
WT
B16-GM-CSF
X-CGD
B16-GM-CSF
Exp. 1 0/5 (0%) 0/5 (0%) 8/10 (80%) 3/10 (30%)
Exp. 2 0/5 (0%) 0/5 (0%) 8/10 (80%) 3/10 (30%)
Exp. 3 0/5 (0%) 0/5 (0%) 9/10 (90%) 4/10 (40%)
Wild-type (WT), iNOS2/2, and X-CGD C57BL/6 mice were injected
subcutaneously in the left flank with 106 irradiated (50 Gy) BI6-GM-
CSF cells. Mice were challenged 2 wk later in the right flank with 105
live B16-WT cells. Results are presented as number of tumor free survi-
vors after 8 wk over the total number of mice. P 5 0.0084 by two-
sided Fisher’s exact test comparing vaccinated wild-type and NOS2/2
mice. Fisher’s exact test (rather than the x2 test) was used to test the dif-
ference in the proportion of tumor-free survivors comparing vaccinated
wild-type versus NOS2/2 mice because of the small numbers of ex-
pected and observed vaccinated wild-type mice that developed tumors.
The test suggests a significant difference between the proportion of tu-
mor-free survivors in the wild-type and NOS2/2 mice (P 5 0.0084),
with an odds ratio of 15.54 (95% confidence interval: 1.73–139.65 using
Woolf’s procedure). P 5 0.001 by x2 test comparing vaccinated wild-
type and X-CGD mice.2364 The Role of CD4+ T Cells in Antitumor Immunity
Th differentiation and the direct inhibition of macrophage
activation by IL-4 and IL-10 (22, 56, 60, 86–88), BALB/c
mice fail to mount effective immunity against L. major
challenge. In contrast, protective immunity against hel-
minth infections, such as Schistosoma mansoni and Nippostro-
gylus brasiliensis, is associated with Th2 development and
the induction of IL-4 (26, 27, 89).
In each of these models, the definitive demonstration
that particular Th1 or Th2 cytokines are critical in direct-
ing appropriate immune responses comes from the finding
that elimination of a given cytokine, either by in vivo anti-
body depletion or by genetic knockout, results in a loss of
protection against the particular pathogen. For example,
g-IFN blockade renders formerly resistant mice susceptible
to L. major infection (90, 91). In addition, administration of
anti–IL-4 antibody to BALB/c mice renders them resistant
to L. major infection (92). Conversely, IL-4 blockade or
IL-12 administration renders resistant mice susceptible to
the helminth infections Trichuris muris, Heligmosomoides po-
lygyrus, and N. brasiliensis infections (29, 93, 94).
In these models, a Th0 response, characterized by a mix-
ture of Th1 and Th2 cytokines, is often seen initially.
However, the immune response in these models typically
commits along Th1 or Th2 lines by 1–2 wk after infectious
challenge (90, 92, 95–97). It is still not known whether the
dual Th1/Th2 phenotype in this antitumor response is pro-
duced by one or two different populations of Th cells.
However, because the RT-PCR cytokine data at the chal-
lenge site were obtained 18 d after vaccination, the mice
most likely had already differentiated past the Th0 stage.
Furthermore, the finding that complete rejection of chal-
lenge tumors introduced 2 wk after vaccination requires
both IL-4 and g-IFN–dependent responses suggests that
the dual Th1/Th2 response persists for an extended period
of time.
It also remains to be determined whether the dual Th1/
Th2 effector response seen here is a general characteristic of
other cell-based tumor vaccines, or is unique to the mech-
anism by which paracrine GM-CSF production initiates
immune responses. Interestingly, a similar Th1/Th2 pat-
tern was seen in response to a defined tumor antigen, i.e., a
B cell lymphoma idiotype protein after immunization with
GM-CSF producing lymphoma cells (98). Further charac-
terization of the Th response made by antigen-specific T
cells in response to tumor vaccination is being performed
currently using TCR transgenic mice specific for a defined
tumor antigen. It is likely that one of the reasons for the su-
periority of paracrine GM-CSF vaccines relative to other
cytokine-transduced vaccines relates to the central role of
GM-CSF in inducing bone marrow progenitors to differ-
entiate into dendritic cells. Currently, we are attempting to
determine whether dendritic cells that differentiate under
GM-CSF control are uniquely capable of inducing and
maintaining Th1 and Th2 differentiation simultaneously.
These findings of induction and maintenance of simulta-
neous Th1 and Th2 responses are somewhat surprising,
given that Th1-associated cytokines such as IL-12 and
g-IFN inhibit Th2 differentiation and Th2-associated cyto-
kines such as IL-4 and IL-10 inhibit Th1 differentiation.
Currently, we do not know whether the dual Th1/Th2 re-
sponse is based on the development of Th cells that simul-
taneously produce Th1 and Th2 cytokines, or a mixture of
separate Th1 and Th2 populations. Nonetheless, the find-
ing that Th1 and Th2 effector mechanisms can actually col-
laborate with each other in directing an effective antitumor
response rather than antagonizing each other has important
implications for the development of cancer immunothera-
pies in general. Ultimately, the most effective cancer im-
munotherapies may indeed be those that can simulta-
neously marshal multiple Th1 and Th2 effector mechanisms
that can cooperate in most effectively killing both the pri-
mary cancer and metastatic tumor deposits.
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